Depression is a complex and deeply personal experience. While almost everyone has periods of sadness, low mood or grief, ...

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults, Johnson & Johnson announced. Lumateperone was previously ...

Please provide your email address to receive an email when new articles are posted on . Among 336 patients with asthma, 46 also had major depressive disorder. There were longitudinal associations ...

The US FDA has approved lumateperone (Caplyta, Johnson & Johnson) for use as adjunctive therapy with antidepressants for the treatment of adults with major depressive disorder (MDD). The approval of ...

A team of leading clinical research scientists from the Departments of Psychiatry and Dermatology at the Icahn School of Medicine at Mount Sinai has found that the serum of patients with major ...

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the ...

Study highlights the uniqueness of individual brain functional connectomes as a promising approach to identify biomarkers for major depressive disorder Major depressive disorder (MDD) is a ...

Persistent depressive disorder, known as dysthymia or low-grade depression, is less severe than major depression but more chronic. It occurs twice as often in women as in men. Persistent depressive ...